{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.8","upperLimit":"90.4","value":"76.5"},{"groupId":"OG001","lowerLimit":"100.0","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"27.6","upperLimit":"73.0","value":"52.9"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.1","upperLimit":"86.6","value":"70.6"},{"groupId":"OG001","lowerLimit":"100.0","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"27.6","upperLimit":"73.0","value":"52.9"}]}],"title":"1 Year"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"The probability of survival at 6 months and 1 year, respectively, after the date of the first dose based on the Kaplan-Meier estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"In ALK genetic event positive participants with ALCL, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG000","title":"ALCL Arm"},{"description":"In ALK genetic event positive participants with IMT, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG001","title":"IMT Arm"},{"description":"In ALK genetic event positive participants with other tumors (excluding non-small cell lung cancer), crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG002","title":"Other Tumors"}],"paramType":"NUMBER","populationDescription":"Enrolled participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"At 6 months and 1 year after first dose","title":"Percentage of Participants Surviving at 6 Months and 1 Year","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}